JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (7): 982-986.doi: 10.3969/j.issn.1674-8115.2021.07.023

• Review • Previous Articles    

Application and prospect of chimeric antigen receptor-modified T cell therapy for glioblastoma

Paerhati NADINA(), Yan YAN, Qian-ji CHE, Jing LUO, Xin-nan LIU, Bin LI()   

  1. Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2021-07-28 Published:2021-08-03
  • Contact: Bin LI;
  • Supported by:
    The 13th Innovation Project of Shanghai Jiao Tong University School of Medicine(1319003)


Glioblastoma is one of the most common and deadly neoplasms in adults. The rapid progress and strong invasiveness of glioblastoma and the presence of the blood-brain barrier make the treatment of glioblastoma different from other solid tumors and these are the reasons for the poor prognosis of conventional treatment. The exploration of immunotherapy in the treatment of glioblastoma has lasted for decades, but the outcome is not good yet. However, with the research progress of glioblastoma-specific antigen, the development of various related technologies and the success of early clinical trials, it has come back to people's attention. Chimeric antigen receptor-modified T cell(CAR-T) is a new kind of tumor immunotherapy. Reviewing the previous literatures, this article summarizes some related antigens that can be used to CAR-T therapy to treat glioblastoma, the problems and challenges faced by CAR-T therapy in the treatment of glioblastoma and other solid tumors, including T cell depletion in tumor microenvironment, heterogeneity of tumor and low homing rate, and some potential improvements in CAR-T therapy.

Key words: chimeric antigen receptor-modified T cell (CAR-T), immunotherapy, glioblastoma, heterogeneity, tumor microenvironment

CLC Number: